Human medicines European public assessment report (EPAR): Kalydeco, ivacaftor, Date of authorisation: 23/07/2012, Revision: 44, Status: Authorised

Human medicines European public assessment report (EPAR): Kalydeco, ivacaftor, Date of authorisation: 23/07/2012, Revision: 44, Status: Authorised

Orphan designation: 3-(5-(2-Hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1H-indole-7-carbonitrile Treatment of X-linked spinal and bulbar muscular atrophy (Kennedy's disease), 10/11/2024 Positive

Orphan designation: 3-(5-(2-Hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1H-indole-7-carbonitrile Treatment of X-linked spinal and bulbar muscular atrophy (Kennedy's disease), 10/11/2024 Positive

Orphan designation: 4,9-Dimethyl-6-(4'-aminophenyl)-2H-furo[2,3-h]-1-benzopyran-2-one Treatment of cystic fibrosis, 10/11/2024 Positive

Orphan designation: 4,9-Dimethyl-6-(4'-aminophenyl)-2H-furo[2,3-h]-1-benzopyran-2-one Treatment of cystic fibrosis, 10/11/2024 Positive

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness